Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 16, 2015 - Issue 12
Submit an article Journal homepage
2,350
Views
11
CrossRef citations to date
0
Altmetric
Editorial

Why are there no FDA-approved treatments for female sexual dysfunction?

Rossella E NappiUniversity of Pavia, IRCCS Policlinico San Matteo, Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, Piazzale Golgi 2, 27100 Pavia, Italy+39 0382 501561; +39 0382 423233; [email protected]
, MD PhD
Pages 1735-1738 | Published online: 13 Jul 2015

Bibliography

  • Hawkes S. Sexual health: a post-2015 palimpsest in global health? Lancet Glob Health 2014;2:e377-8
  • Goldstein I. Raising the glass ceiling: not all “men” are created equal. J Sex Med 2014;11:1885-7
  • American Psychiatric Association. Highlights of changes from DSM-IV-TR to DSM-5. American Psychiatric Press, Washington DC; 2013
  • Nappi RE, Cucinella L. Advances in pharmacotherapy for treating female sexual dysfunction. Expert Opin Pharmacother 2015;16:875-87
  • Bradford A. Listening to placebo in clinical trials for female sexual dysfunction. J Sex Med 2013;10:451-9
  • Bitzer J, Giraldi A, Pfaus J. A standardized diagnostic interview for hypoactive sexual desire disorder in women: standard operating procedure (SOP Part 2). J Sex Med 2013;10:50-7
  • Chivers ML, Rosen RC. Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms? J Sex Med 2010;7:858-72
  • Nappi RE, Domoney C. Pharmacogenomics and sexuality: a vision. Climacteric 2013;16(Suppl 1):25-30
  • Portman DJ, Gass ML; Vulvovaginal atrophy terminology consensus conference panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American Menopause Society. J Sex Med 2014;11:2865-72
  • Wierman ME, Nappi RE, Avis N, et al. Endocrine aspects of women’s sexual function. J Sex Med 2010;7:561-85
  • Davis SR, Worsley R. Androgen treatment of postmenopausal women. J Steroid Biochem Mol Biol 2014;142:107-14
  • Avis NE, Brockwell S, Randolph JF, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women’s Health Across the Nation. Menopause 2009;16:442-52
  • Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric 2012;15:267-74
  • Thorp JJr, Palacios S, Symons J, et al. Improving prospects for treating hypoactive sexual desire disorder (HSDD): development status of flibanserin. BJOG 2014;121:1328-31
  • Goldstein I. Effect of food and drug administration decisions on sexual medicine research. J Sex Med 2014;11:2623-4

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.